Diplomat Pharmacy (DPLO) Misses Q3 EPS by 3c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Wall St set to open lower as Trump says Iran deal is 'over'
- Oil jumps around 5% to two-week high after Trump warns of more attacks on Iran
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
Avondale Partners Downgrades Diplomat Pharmacy (DPLO) to Market Perform
November 3, 2016 7:42 AM EDTAvondale Partners downgraded Diplomat Pharmacy (NYSE: DPLO) from Market Outperform to Market Perform.
For an analyst ratings summary and ratings history on Diplomat Pharmacy click here. For more ratings news on Diplomat Pharmacy click here.
Shares of Diplomat Pharmacy closed at $22.38 yesterday.
... MoreLeerink Partners Downgrades Diplomat Pharmacy (DPLO) to Market Perform
November 3, 2016 6:59 AM EDTLeerink Partners downgraded Diplomat Pharmacy (NYSE: DPLO) from Outperform to Market Perform with a price target of $18.00 (from $35.00).
Analyst David Larsen commented, "Yesterday afternoon DPLO reduced its outlook for 2016 and provided a preliminary outlook for 2017 that was well below expectations. As a... More
